Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FEN1 | P39748 | 12/20 | 0.38 |
| ▸ | ALOX5AP | P20292 | 11/20 | 0.38 |
| ▸ | NSD2 | O96028 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.35 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.35 |
| ▸ | AKT1 | P31749 | 1/20 | 0.35 |
| ▸ | AKT2 | P31751 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2679108 | 0.93 | FEN1 (0.38) | FEN1ALOX5APAPPCYP3A4CYP2C19 | |
| SCHEMBL2678746 | 0.84 | HSD11B1 (0.40) | CYP3A4CYP2C19CYP2C9HSD11B1 | |
| SCHEMBL2678244 | 0.84 | HSD11B1 (0.41) | HSD11B1 | |
| SCHEMBL2678219 | 0.82 | HPGDS (0.43) | HSD11B1 | |
| SCHEMBL4463296 | 0.82 | HSD11B1 (0.40) | HSD11B1 | |
| Bromide SCHEMBL4471147 | 0.81 | HSD11B1 (0.39) | HSD11B1 | |
| SCHEMBL4466231 | 0.81 | HPGDS (0.41) | HSD11B1 | |
| SCHEMBL2678520 | 0.80 | DKK1 (0.41) | CYP2C19CYP2C9 | |
| SCHEMBL2679330 | 0.80 | HSD11B1 (0.41) | NSD2CYP3A4HSD11B1 | |
| SCHEMBL2678187 | 0.80 | NPC1 (0.39) | FEN1ALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8759343-B2 | Azabicycloalkane derivatives, preparation thereof and use thereof in therapy | SANOFI (FR) | 2014-06-24 | — | — | US | disclosed |
| EP-2118104-B1 | AZABICYCLOALKANE DERIVATIVES, PREPARATION THEREOF AND USE THEREOF IN THERAPY | SANOFI SA (FR) | 2013-01-02 | — | — | EP | disclosed |
| US-20120202807-A1 | AZABICYCLOALKANE DERIVATIVES, PREPARATION THEREOF AND USE THEREOF IN THERAPY | SANOFI (FR) | 2012-08-09 | — | — | US | disclosed |
| US-8173669-B2 | Azabicycloalkane derivatives, preparation thereof and use thereof in therapy | SANOFI-AVENTIS (FR) | 2012-05-08 | — | — | US | disclosed |
| US-20100035916-A1 | AZABICYCLOALKANE DERIVATIVES, PREPARATION THEREOF AND USE THEREOF IN THERAPY | SANOFI-AVENTIS (FR) | 2010-02-11 | — | — | US | disclosed |
| EP-2118104-A2 | AZABICYCLOALKANE DERIVATIVES, PREPARATION THEREOF AND USE THEREOF IN THERAPY | Sanofi-Aventis (FR) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008110699-A2 | AZABICYCLOALKANE DERIVATIVES, PREPARATION THEREOF AND USE THEREOF IN THERAPY | SANOFI-AVENTIS (FR) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202807-A1 | AZABICYCLOALKANE DERIVATIVES, PREPARATION THEREOF AND USE THEREOF IN THERAPY | TPMT, CYP51A1, ABL1 | FEN1 1637/4885ALOX5AP 666/4885NSD2 1453/4885 |
| US-20100035916-A1 | AZABICYCLOALKANE DERIVATIVES, PREPARATION THEREOF AND USE THEREOF IN THERAPY | TPMT, CYP51A1, ABL1 | FEN1 1637/4885ALOX5AP 666/4885NSD2 1453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.